Discovery of potent wall teichoic acid early stage inhibitors

Area of Science:

• Microbiology
• Medicinal Chemistry
• Antibiotic Resistance

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat due to resistance to beta-lactam antibiotics.
• There is an urgent need for novel therapeutic strategies to overcome MRSA infections.

Purpose of the Study:

• To identify novel inhibitors targeting the early stages of wall teichoic acid (WTA) biosynthesis.
• To evaluate the synergistic potential of these inhibitors with beta-lactam antibiotics against MRSA.

Main Methods:

• Phenotypic screening of Staphylococcus aureus to identify small molecule inhibitors.
• Genetic and biochemical assays to confirm TarO inhibition (the first step in WTA biosynthesis).
• Testing the synergy of identified inhibitors (tarocins) with broad-spectrum beta-lactams against diverse MRSA clinical isolates.

Main Results:

• Identification of tarocins, small molecule inhibitors of TarO, crucial for WTA biosynthesis.
• Demonstration of potent bactericidal synergy between tarocins and beta-lactam antibiotics.
• Tarocins exhibit efficacy across various clinical isolates of methicillin-resistant Staphylococci.

Conclusions:

• Tarocins represent a novel class of compounds targeting the WTA pathway.
• The combination of tarocins with beta-lactams offers a rational approach to developing new treatments for MRSA.
• WTA pathway inhibitors hold promise for combating Gram-positive bacterial infections, including those caused by MRSA.